{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:11:30Z","timestamp":1787155890485,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2018\/30\/E\/NZ6\/00696"],"award-info":[{"award-number":["UMO-2018\/30\/E\/NZ6\/00696"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.meegid.2021.104949","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T12:32:02Z","timestamp":1622550722000},"page":"104949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["HCV resistance-associated substitutions following direct-acting antiviral therapy failure \u2013 Real-life data from Poland"],"prefix":"10.1016","volume":"93","author":[{"given":"Mi\u0142osz","family":"Parczewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Pisula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Dybowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142adys\u0142aw","family":"\u0141ojewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Witor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Wawrzynowicz-Syczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Socha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Krygier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brygida","family":"Knysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Musialik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Urba\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Scheibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2021.104949_bb0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jcv.2015.07.310","article-title":"HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study","volume":"72","author":"Bartolini","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.meegid.2021.104949_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0015","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/liv.12848","article-title":"Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?","volume":"35","author":"Boesecke","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.meegid.2021.104949_bb0020","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2021.104949_bb0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0030","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2021.104949_bb0035","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients","volume":"10","author":"Dietz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2021.104949_bb0045","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3109\/14756366.2013.864651","article-title":"Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors","volume":"29","author":"Ehrenberg","year":"2014","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.meegid.2021.104949_bb0050","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"European Association for the Study of the Liver","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","article-title":"Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study","volume":"2","author":"European Union, H.C.V.C","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/jvh.13254","volume":"27","author":"Fedorchenko","year":"2020","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.meegid.2021.104949_bb0065","first-page":"163","article-title":"Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection","volume":"130","author":"Flisiak","year":"2020","journal-title":"Pol. Arch Intern. Med."},{"key":"10.1016\/j.meegid.2021.104949_bb0070","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","volume":"63","author":"Forns","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2014.01.010","article-title":"The competitive binding between inhibitors and substrates of HCV NS3\/4A protease: a general mechanism of drug resistance","volume":"103","author":"Guan","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2021.104949_bb0080","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1039\/C5MB00394F","article-title":"Exploring resistance mechanisms of HCV NS3\/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations","volume":"11","author":"Guan","year":"2015","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.meegid.2021.104949_bb0085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5114\/ceh.2020.98606","article-title":"Recommendations of the polish group of experts for HCV for the treatment of hepatitis C in 2020","volume":"6","author":"Halota","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2014.10.010","article-title":"Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C","volume":"113","author":"Howe","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2021.104949_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jiz154","volume":"220","author":"Huang","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2021.104949_bb0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00535-016-1225-x","article-title":"Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1","volume":"52","author":"Iio","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.meegid.2021.104949_bb0110","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.jhepr.2020.100138","article-title":"Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C","volume":"2","author":"Itakura","year":"2020","journal-title":"JHEP Rep."},{"key":"10.1016\/j.meegid.2021.104949_bb0115","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"O057: Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r-, ombitasvir- and dasabuvir-based regimens","volume":"62","author":"Krishnan","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0120","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2021.104949_bb0125","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"O057: Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r-, ombitasvir- and dasabuvir-based regimens","volume":"62","author":"Krishnan","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0130","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2021.104949_bb0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-\u03b1 therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"issue":"11\u201316","key":"10.1016\/j.meegid.2021.104949_bb0140","first-page":"99","article-title":"Distribution of HCV genotypes in Poland","volume":"67","author":"Panasiuk","year":"2013","journal-title":"Przegl. Epidemiol."},{"key":"10.1016\/j.meegid.2021.104949_bb0145","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cmi.2018.06.028","article-title":"Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters","volume":"25","author":"Parczewski","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.meegid.2021.104949_bb0150","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2021.104949_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"Ribeiro","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.meegid.2021.104949_bb0160","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jmv.24213","article-title":"Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV","volume":"87","author":"Silva","year":"2015","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.meegid.2021.104949_bb0165","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.meegid.2021.104949_bb0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2021.104949_bb0175","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41598-018-21303-2","article-title":"Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir\/sofosbuvir or simeprevir\/sofosbuvir against GT1 HCV infection","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.meegid.2021.104949_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/bab.1479","article-title":"Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339","volume":"64","author":"Wang","year":"2017","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.meegid.2021.104949_bb0185","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.coviro.2012.07.007","article-title":"Viral fitness: definitions, measurement, and current insights","volume":"2","author":"Wargo","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.meegid.2021.104949_bb0190","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","author":"Woods","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.meegid.2021.104949_bb0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jvh.12230","article-title":"Importance of HCV genotype 1 subtypes for drug resistance and response to therapy","volume":"21","author":"Wyles","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.meegid.2021.104949_bb0200","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jmv.24255","article-title":"Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy","volume":"87","author":"Yoshimi","year":"2015","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.meegid.2021.104949_bb0205","doi-asserted-by":"crossref","first-page":"4029541","DOI":"10.1155\/2019\/4029541","article-title":"Real world experience of chronic hepatitis C retreatment with genotype specific regimens in nonresponders to previous interferon-free therapy","volume":"2019","author":"Zarebska-Michaluk","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.meegid.2021.104949_bb0210","series-title":"A Randomized, Controlled, Phase 3 Trial of Sofosbuvir\/Velpatasvir\/Voxilaprevir or Sofosbuvir\/Velpatasvir for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1\u20136 HCV Infection: The POLARIS-4 Study","volume":"63","author":"Zeuzem","year":"2020"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156713482100246X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156713482100246X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:54:16Z","timestamp":1761576856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156713482100246X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":42,"alternative-id":["S156713482100246X"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2021.104949","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HCV resistance-associated substitutions following direct-acting antiviral therapy failure \u2013 Real-life data from Poland","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2021.104949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104949"}}